Navigation Links
GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, Inc. (Nasdaq:GNVC) announced today data from two studies presented at the 97th annual meeting of the American Association of Cancer Research (AACR) that further support the use of adenovector systems to deliver the gene for tumor necrosis factor-alpha (TNF(alpha)). GenVec's lead product candidate, TNFerade(TM) biologic (TNFerade) is an adenovector, or DNA carrier, which contains the gene for TNF(alpha), a potent immune system protein with well-documented anti-cancer effects. TNFerade is currently in a pivotal Phase II/III trial for locally advanced pancreatic cancer.

GenVec researchers presented a poster entitled, "Selective delivery of tumor necrosis factor to disseminated tumors in the peritoneal cavity using targeted adenovirus vectors," (Abstract #3310) which confirmed the ability of its molecularly targeted adenovectors to selectively deliver genes to cancer cells in the peritoneal cavity in several animal models. These data demonstrated the ability of targeted vectors to penetrate tumor tissue and trigger protein expression in a dose dependent manner. This pre-clinical research suggests that tumor selective adenovectors can preferentially deliver the TNF-(alpha) gene, and holds promise as a treatment for ovarian cancer.

The mechanism of action of TNF(alpha) was the subject of a second poster presentation entitled, "The anti-tumor effects of radio-inducible TNF-alpha gene therapy target host stromal components," (Abstract #1382). In studies conducted at the University of Chicago, TNF-(alpha) delivered in an adenovector, in combination with radiation therapy, showed key effects on stromal tissues and blood vessels, both of which are critical components of human solid tumors. These results support the potential of broad activity in many tumor types.

"These results demonstrate two key findings, a potentially important mechanism of action of TNF(alpha), and the ability of adenovectors to selectively deliver the TNF(alpha) gene to cancer cells," stated C. Richter King, Ph.D., GenVec's Senior Vice President of Research. "These findings support the broad applicability of our core technology for use in the treatment of cancer," added Dr. King.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, and seasonal and pandemic flu. Additional information about GenVec is available at and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product cand idates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


GenVec, Inc.
Sharon L. Weinstein, 240-632-5511


Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Presents Research on New Ad35 Adenovector at ARVO
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two ... American children and adults, according to a new study by researchers at the School ... in Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers ...
(Date:11/30/2015)... ... ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, is ... in 1935. His father graduated from NYU School of Dentistry in 1965. ... their commitment and passion to the Practice of Dentistry. Continuing the family practice ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for ... honor of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a ... about World AIDS Day and the importance of getting tested for HIV. , ASCP ...
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
Breaking Medicine News(10 mins):